Ottobock SE KGaA (OBCK) Stock Overview
Develops, produces, and distributes medical technology products and components for the people with disabilities in the fields of prosthetics, orthotics, human mobility, and industrial exoskeletons in Europe, the Middle East, Africa, North and South America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
OBCK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ottobock SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €53.50 |
| 52 Week High | €76.35 |
| 52 Week Low | €45.56 |
| Beta | 0 |
| 1 Month Change | 1.90% |
| 3 Month Change | -1.02% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| OBCK | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 4.5% | 0.9% | 0.6% |
| 1Y | n/a | -28.6% | 1.1% |
Return vs Industry: Insufficient data to determine how OBCK performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how OBCK performed against the German Market.
Price Volatility
| OBCK volatility | |
|---|---|
| OBCK Average Weekly Movement | 5.9% |
| Medical Equipment Industry Average Movement | 5.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 13.4% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: OBCK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: OBCK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1919 | 9,486 | Oliver Jakobi | corporate.ottobock.com/en/home |
Ottobock SE & Co. KGaA develops, produces, and distributes medical technology products and components for the people with disabilities in the fields of prosthetics, orthotics, human mobility, and industrial exoskeletons in Europe, the Middle East, Africa, North and South America, and the Asia Pacific. The company is involved in identification, development, manufacturing, sales, and marketing of prosthetics, neuro-orthotics, and digital solutions; prostheses for the upper and lower extremities; mechanical prostheses and technologically sophisticated microprocessor-controlled; prosthetic knee joints and feet; arm and hand prostheses; and myoelectrical prostheses activities, as well as socket technologies, including liners, intelligent adaptors, and cosmetic components. It also provides fitting solutions for neurological indications; microprocessor-controlled orthotics, such as the C-Brace; and electrical muscle-activating stimulators, including exopulse suit and conventional orthotics; planning and equipping of patient care clinics; solutions for back, shoulder, neck, and wrist; customized orthopedic treatment and rehabilitation solutions; manual and power wheel chair; and standing aids and cushions, as well as care for amputees, including peripheral artery disease, traumatic limb loss, cancer, infections, congenital limb deficiencies, etc; and neurological etiologies, including stroke, multiple sclerosis, cerebral palsy/spinal cord injury, etc. In addition, the company leases out products, including wheelchairs and microprocessor-controlled knee joints.
Ottobock SE & Co. KGaA Fundamentals Summary
| OBCK fundamental statistics | |
|---|---|
| Market cap | €3.42b |
| Earnings (TTM) | €91.80m |
| Revenue (TTM) | €1.69b |
Is OBCK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBCK income statement (TTM) | |
|---|---|
| Revenue | €1.69b |
| Cost of Revenue | €795.00m |
| Gross Profit | €898.00m |
| Other Expenses | €806.20m |
| Earnings | €91.80m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 13, 2026
| Earnings per share (EPS) | 1.43 |
| Gross Margin | 53.04% |
| Net Profit Margin | 5.42% |
| Debt/Equity Ratio | 213.5% |
How did OBCK perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/01 11:29 |
| End of Day Share Price | 2026/07/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ottobock SE & Co. KGaA is covered by 7 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beatrice Fairbairn | Berenberg |
| Hugo Solvet | BNP Paribas |
| Anna Ractliffe | BofA Global Research |